# India Ophthalmic Drugs Devices Market > India Ophthalmic Drugs and Devices Market Research Report By Product (Drugs, Devices) and By Treatment (Eye Infections, Allergic Conjunctivitis, Dry Eyes Syndrome, Red Eyes, Inflammation, Others) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 5.14% - **2024:** $ 2.18 Billion - **2025:** $ 2.33 Billion - **2035:** $ 3.79 Billion - **Key Players:** Novartis (CH), Allergan (IE), Bausch + Lomb (CA), Johnson & Johnson (US), Santen Pharmaceutical (JP), Alcon (CH), Merck (DE), Pfizer (US), Hoya Corporation (JP) **Report ID:** MRFR/Pharma/51786-HCR · **Pages:** 200 · **Author:** Vikita Thakur & Garvit Vyas · **Last Updated:** March 28, 2026 **URL:** https://www.marketresearchfuture.com/reports/india-ophthalmic-drugs-devices-market-53547 --- ## Market Summary ## **India Ophthalmic Drugs and Devices Market Overview** As per MRFR analysis, the India Ophthalmic Drugs and Devices Market Size was estimated at 2.29 (USD Billion) in 2023. The India Ophthalmic Drugs and Devices Market is expected to grow from 2.5 (USD Billion) in 2024 to 12.5 (USD Billion) by 2035. The India Ophthalmic Drugs and Devices Market CAGR (growth rate) is expected to be around 15.756% during the forecast period (2025 - 2035). ### **Key India Ophthalmic Drugs and Devices Market Trends Highlighted** The growth of the India ophthalmic drugs and devices market is being significantly fueled by the increasing occurrence of eye disorders, particularly resulting from the aging demographic and the growing rate of diabetes-associated vision problems. Government programs for promoting eye care like the National Programme for Control of Blindness also aid in growing the market. There is also improved patient outcome with the new innovative treatment devices developed due to changes in the technologies. Greater awareness and adoption of preventive eye care, as well as the use of telemedicine for eye care in distant locations, unlock greater scope in the market. These days, there is a distinct movement towards personalized medicine in ophthalmology as treatments are designed to individual patients based on their genetics and environment. Moreover, the development of digital health technologies, such as mobile eye care and teleconsultation apps, offers new opportunities for advancement. Patients’ preference for outpatient procedures with fast recovery times is also shifting the landscape due to the trend towards minimally invasive surgeries and sophisticated drug delivery systems. There is still a large gap in the market when it comes to affordable and economical eyecare, which emphasizes the need for local industries, as well as collaboration with international pharmaceutical and medical device companies. With increased government initiatives aimed at improving healthcare facilities and additional investment from the private sector, it is certain the India ophthalmic drugs and devices market will grow and thrive as an integral part of the country’s healthcare ecosystem. ## **India Ophthalmic Drugs and Devices Market Drivers** ### **Rising Prevalence of Eye Disorders** India is witnessing a dramatic increase in the prevalence of eye disorders such as diabetic retinopathy, cataract, and age-related macular degeneration. According to the National Programme for Control of Blindness and Visual Impairment (NPCBVI), about 62 million people in India are suffering from refractive errors, and this number is expected to grow with the increasing diabetes prevalence, which has seen a 60% increase in the last decade. The alarming rise in conditions like diabetic retinopathy, which affects approximately 18 million individuals, necessitates increased demand for both ophthalmic drugs and devices. Major organizations like the All India Ophthalmological Society are actively working to raise awareness and develop strategies for the effective management of these diseases, contributing to the growth of the India Ophthalmic Drugs and Devices Market. ### **Advancements in Ophthalmic Technology** Innovations in ophthalmic technology are significantly enhancing the treatment landscape in India. The introduction of minimally invasive surgical procedures and advanced diagnostic devices has transformed patient experiences and treatment outcomes. For instance, the launch of femtosecond lasers and Optical Coherence Tomography (OCT) has proven to reduce recovery time and improve accuracy, making surgeries safer and more efficient. The Indian medical device industry is projected to grow at a CAGR of over 25% as a result of these technological advancements, according to the Association of Indian Medical Device Industry. Such technological progress is a key driver for growth in the India[Ophthalmic Drugs and Devices](../../../reports/ophthalmic-drugs-devices-market-10922) Market. ### **Government Initiatives and Funding** The Indian government has ramped up its focus on eye health through various initiatives and programs. The National Health Mission is putting significant resources into vision care, aiming to reduce preventable blindness by promoting awareness and providing subsidized drugs and devices for lower-income populations. In recent years, the government has allocated substantial funding, surpassing 10 billion INR for eye health programs, which has opened opportunities for major players like Alcon and Johnson & Johnson Vision to expand their operations in India. These initiatives indicate a supportive policy environment, which directly fuels growth in the India Ophthalmic Drugs and Devices Market. ## **India Ophthalmic Drugs and Devices Market Segment Insights** ### **Ophthalmic Drugs and Devices Market Product Insights** The India Ophthalmic Drugs and Devices Market showcases a diverse range of products that play a crucial role in addressing various eye conditions and enhancing the quality of vision care. The market is characterized by an array of ophthalmic drugs and devices, which cater to the growing prevalence of eye-related disorders, particularly due to the increase in lifestyle-related factors and an aging population. The importance of ophthalmic drugs lies in their ability to treat a variety of conditions, including glaucoma, cataracts, and dry eye syndrome. Pharmacological innovations have been significant in this market, emphasizing the development of targeted therapies that offer better treatment outcomes and improved patient adherence. On the devices side, advancements in technology have led to significant improvements in surgical equipment and diagnostic tools, bolstering the efficacy and precision of ophthalmic procedures. Devices such as surgical lasers, intraocular lenses, and diagnostic imaging equipment, including optical coherence tomography, are in high demand, underscoring their essential role in contemporary eye care practice. The increasing focus on patient-centered healthcare models has propelled growth in both segments, as healthcare providers seek to offer tailored and efficient solutions to patients. Industry trends indicate a notable shift toward less invasive surgical options, which are more appealing to patients. As the Indian population ages and the incidence of eye conditions rises, the demand for effective therapeutic options and innovative medical devices is likely to expand, defining the strategic landscape of the India Ophthalmic Drugs and Devices Market. The segmentation within the ophthalmic drugs and devices sector highlights a clear understanding of market dynamics, with players continuously investing in Research and Development to innovate and differentiate their offerings. Enhanced awareness about eye health and regular screenings are encouraging patients to seek treatment earlier, further driving growth across these products. The competitive landscape also features a mix of established global and emerging local players, making it vital for companies to adapt their strategies to meet the unique needs of the Indian market. Additionally, government initiatives aimed at improving healthcare infrastructure and increasing accessibility to eye care services contribute significantly to market expansion, positioning the India Ophthalmic Drugs and Devices Market for robust growth in the coming years. ### **Ophthalmic Drugs and Devices Market Treatment Insights** The Treatment segment of the India Ophthalmic Drugs and Devices Market is witnessing significant growth driven by the increasing prevalence of various eye conditions among the population. Eye infections remain a dominant concern, often exacerbated by environmental factors and a lack of awareness about hygiene practices. Allergic conjunctivitis is also prevalent, especially in urban areas due to rising pollution levels and allergens, highlighting the need for effective treatment options. Dry eyes syndrome is becoming increasingly common due to prolonged exposure to digital screens, which has prompted the demand for moisturizing eye drops and therapies. The concern over red eyes and inflammation signifies a need for anti-inflammatory medications and treatments that are crucial for maintaining eye health. Moreover, other conditions such as glaucoma and cataracts are prevalent in the aging population, leading to an expanding landscape of therapeutic options. The overall dynamics around this segment suggest a robust opportunity for pharmaceutical companies and healthcare providers to focus on innovative treatments that cater to the diverse needs of the Indian population, indicating favorable India Ophthalmic Drugs and Devices Market statistics and revenue growth potential in the coming years. ## **India Ophthalmic Drugs and Devices Market Key Players and Competitive Insights** The India Ophthalmic Drugs and Devices Market showcases a dynamic environment characterized by rapid innovation and an increasing focus on addressing the growing prevalence of eye disorders. This market is heavily influenced by the rising demand for advanced ophthalmic solutions, including drugs for conditions such as glaucoma, dry eye, and retinal diseases, as well as a wide array of surgical instruments and diagnostic devices. Competitive insights indicate that companies are not only focusing on enhancing the efficacy of their products but are also investing significantly in research and development to introduce cutting-edge technologies and solutions. The landscape is marked by collaborations, partnerships, and strategic alliances that aim to expand market reach and improve distribution channels, ultimately benefiting patients through better accessibility to ophthalmic care. Allergan maintains a prominent position within the India Ophthalmic Drugs and Devices Market, leveraging its strong portfolio of products that cater to the diverse needs of ophthalmology. The company's strength lies in its innovative drug formulations and commitment to high-quality standards, which have made it a trusted name among healthcare professionals and patients alike. Allergan's focus on addressing conditions like glaucoma and dry eye with advanced therapeutic options showcases its dedication to improving patient outcomes. Additionally, the brand has established a solid market presence through effective marketing strategies and a widespread distribution network, ensuring its products are readily available across various healthcare settings in India. This persistent focus on research and development enables Allergan to stay ahead of industry trends and devise effective solutions for ophthalmic care. Sun Pharmaceutical is another key player in the India Ophthalmic Drugs and Devices Market, recognized for its extensive range of ophthalmic products, including both generic and branded medications. The company's strengths lie in its robust manufacturing capabilities and strong output of high-quality pharmaceutical products, making it a reliable source for various ocular therapies. Sun Pharmaceutical has established a significant presence in the India market through strategic alliances, mergers, and acquisitions that enhance its product offerings and expand its reach. Key products include treatments for glaucoma, retinal diseases, and anti-allergic solutions, which contribute to a comprehensive ophthalmic care portfolio. The company’s commitment to innovation and its ability to adapt to emerging market needs ensure its competitiveness within the ophthalmic segment, addressing the growing concerns of eye health in the region. ### **Key Companies in the India Ophthalmic Drugs and Devices Market Include** ### **India Ophthalmic Drugs and Devices Market Developments** The recent developments in the India Ophthalmic Drugs and Devices Market are marked by significant advancements and activities involving several major players. Allergan and Novartis are expanding their product lines, with recent approvals showcasing innovative treatments in glaucoma and ocular surface disease. In August 2023, Lupin Pharmaceuticals announced a robust pipeline for ophthalmic diseases, emphasizing research efforts aimed at addressing unmet needs in the market. Dr. Reddy's Laboratories continues to strengthen its presence with new partnerships aimed at producing advanced drug delivery systems. Merck launched new therapies targeted for retinal diseases, contributing to growth in market valuation alongside strong competition from Alcon and Johnson and Johnson. In terms of mergers and acquisitions, there has been notable activity, particularly in August 2023, when Aerie Pharmaceuticals acquired a strategic partnership with Bausch Health, further aligning itself in the ophthalmic market. The Indian government's recent initiatives to improve healthcare access, including ophthalmic care, have spurred market growth, with expenditures in healthcare projected to rise significantly by the end of 2024. These developments reflect an evolving landscape where innovation meets rising healthcare demands among the Indian population. ## **India Ophthalmic Drugs and Devices Market Segmentation Insights** ### **Ophthalmic Drugs and Devices Market Product Outlook** ### **Ophthalmic Drugs and Devices Market Treatment Outlook** ## Market Drivers ### Government Policies and Support Government initiatives aimed at improving healthcare access are significantly influencing the India [Ophthalmic Drugs](https://www.marketresearchfuture.com/reports/ophthalmic-drugs-market-5753) Devices Market. The National Health Mission and various state-level programs are focused on enhancing eye care services, particularly in rural areas. These policies often include subsidized treatments and awareness campaigns, which encourage individuals to seek eye care. Furthermore, the government's push for Make in India has led to increased local manufacturing of ophthalmic devices, reducing costs and improving availability. Such supportive measures are likely to stimulate growth in the india ophthalmic drugs devices market, as they create a more favorable environment for both manufacturers and consumers. ### Increasing Prevalence of Eye Disorders The rising incidence of eye disorders in India is a pivotal driver for the India Ophthalmic Drugs Devices Market. With an estimated 62 million people suffering from refractive errors and a significant number affected by cataracts and glaucoma, the demand for effective ophthalmic drugs and devices is surging. This trend is further exacerbated by the aging population, as older individuals are more susceptible to various eye conditions. The increasing prevalence of diabetes, which is linked to diabetic retinopathy, also contributes to the growing market. As awareness of these conditions rises, patients are more likely to seek treatment, thereby propelling the growth of the india ophthalmic drugs devices market. ### Rising Consumer Awareness and Education Consumer awareness regarding eye health is on the rise in India, which is positively impacting the India Ophthalmic Drugs Devices Market. Educational campaigns by non-governmental organizations and healthcare providers are informing the public about the importance of regular eye check-ups and early detection of eye diseases. This heightened awareness is leading to increased demand for ophthalmic drugs and devices, as individuals are more proactive in seeking treatment. Moreover, the proliferation of digital media has facilitated the dissemination of information, making it easier for consumers to understand their eye health needs. As awareness continues to grow, it is likely to drive further expansion in the india ophthalmic drugs devices market. ### Technological Innovations in Ophthalmology Technological advancements in ophthalmic devices are transforming the landscape of the India Ophthalmic Drugs Devices Market. Innovations such as minimally invasive surgical techniques, advanced diagnostic tools, and smart contact lenses are enhancing patient outcomes and driving market growth. For instance, the introduction of femtosecond lasers for cataract surgery has improved precision and reduced recovery times. Moreover, the integration of artificial intelligence in diagnostic equipment is streamlining the detection of eye diseases, making it more efficient. These technological innovations not only improve the quality of care but also attract investments, thereby fostering a competitive environment in the india ophthalmic drugs devices market. ### Growing Investment in Healthcare Infrastructure The expansion of healthcare infrastructure in India is a crucial driver for the India Ophthalmic Drugs Devices Market. With increasing investments in hospitals and clinics, particularly in tier-2 and tier-3 cities, access to eye care services is improving. This growth is supported by both public and private sectors, with numerous initiatives aimed at enhancing healthcare facilities. As more healthcare providers incorporate advanced ophthalmic devices and treatments, the market is expected to witness substantial growth. Additionally, the establishment of specialized eye hospitals is likely to increase the demand for innovative ophthalmic drugs and devices, further propelling the india ophthalmic drugs devices market. ## Future Outlook The India ophthalmic drugs devices market is projected to grow at a 5.14% CAGR from 2025 to 2035, driven by increasing prevalence of eye disorders and technological advancements. **New opportunities:** - Development of teleophthalmology platforms for remote consultations. - Investment in AI-driven diagnostic tools for early detection. - Expansion of personalized medicine approaches in ophthalmic treatments. By 2035, the market is expected to be robust, driven by innovation and increasing demand. ## Segment Insights ### By Application: Cataract Surgery (Largest) vs. Glaucoma Treatment (Fastest-Growing) The India [ophthalmic drugs devices](https://www.marketresearchfuture.com/reports/ophthalmic-drugs-devices-market-10922) market is seeing significant segmentation driven by application areas such as Cataract Surgery, Glaucoma Treatment, Retinal Disorders, Infection Treatment, and Dry Eye Treatment. Among these, Cataract Surgery holds the largest market share, reflecting the high prevalence of cataracts in the aging population. Glaucoma Treatment is rapidly gaining traction and is recognized as the fastest-growing segment due to increasing awareness and advancements in treatment options. Other segments like Retinal Disorders and Infection Treatment also contribute but with relatively smaller shares. Cataract Surgery (Dominant) vs. Glaucoma Treatment (Emerging) Cataract Surgery is the dominant application in the India ophthalmic drugs devices market, primarily due to the high incidence of cataracts among the elderly, prompting a consistent demand for surgical interventions and innovative solutions. The technology surrounding cataract surgery devices is advancing rapidly, enhancing patient outcomes and procedural efficiency. On the other hand, Glaucoma Treatment is identified as an emerging application, driven by the rising incidence of glaucoma and increasing patient awareness toward early diagnosis and treatment. The market is witnessing a shift as new drug formulations and delivery systems are introduced, promising better adherence to therapy and improved safety profiles. Both segments play crucial roles in the evolving ophthalmic landscape. ### By Device Type: Intraocular Lenses (Largest) vs. Contact Lenses (Fastest-Growing) In the India ophthalmic drugs devices market, the device type segment displays a diverse distribution of market shares among its various categories. Intraocular lenses hold the largest share, reflecting their integral role in cataract surgeries and vision correction. Additionally, surgical instruments and diagnostic equipment also occupy significant portions of the market, driven by ongoing advancements in surgical procedures and diagnostic technology. The contact lenses segment, on the other hand, is identified as the fastest-growing category in this market. This growth is fueled by rising awareness of vision care, an increase in myopic and hyperopic patients, and the growing preference for contact lenses over traditional eyeglasses. The overall trend indicates a shift in consumer preference towards more flexible and comfort-oriented vision solutions, promoting innovation in lens materials and designs. Intraocular Lenses: Dominant vs. Contact Lenses: Emerging Intraocular lenses, as a dominant segment in the India ophthalmic drugs devices market, are crucial for enhancing vision post-cataract surgery, making them essential in the overall treatment regimen. They benefit from long-standing consumer trust and consistent demand, driven by an aging population and increasing instances of cataracts. Their market position is supported by continuous innovation and the introduction of various lens types tailored for specific vision requirements. Conversely, contact lenses represent an emerging segment, capturing the interest of younger consumers seeking convenience and aesthetic appeal. As innovations in materials make lenses more comfortable and longer-lasting, this segment is rapidly expanding. Advances in technology are resulting in soft and rigid gas permeable lenses that offer better oxygen permeability, thereby enhancing wearers' experience. Both segments illustrate the dynamic shifts in consumer preferences for vision correction. ### By End User: Hospitals (Largest) vs. Eye Clinics (Fastest-Growing) In the India ophthalmic drugs and devices market, the end user segment is primarily composed of hospitals, eye clinics, home care settings, research institutions, and pharmacies. Among these, hospitals represent the largest share, driven by the comprehensive services they provide and their capacity to treat a high volume of patients. Eye clinics, however, are on a rapid growth trajectory, attracting patients seeking specialized care and quicker services, which has led to their increasing prominence in the market. Hospitals (Dominant) vs. Eye Clinics (Emerging) Hospitals are the dominant end user in the Indian ophthalmic drugs and devices market, offering a wide range of services and advanced surgical options that meet the diverse needs of patients with eye-related conditions. They have established robust infrastructures and are often the first point of contact for emergencies or complex treatments. On the other hand, eye clinics are emerging as critical players, appealing to patients who prefer dedicated eye care services in a more accessible and less intimidating environment. These facilities typically offer personalized services, quicker appointment times, and specialized treatment options, making them a preferred choice among patients seeking timely eye care. ## Competitive Benchmarking The competitive dynamics of the ophthalmic drugs and devices market in India are characterized by a blend of innovation, strategic partnerships, and regional expansion. Key growth drivers include an increasing prevalence of eye disorders, a rising geriatric population, and advancements in technology. Major players such as Novartis (CH), Johnson & Johnson (US), and Alcon (CH) are actively shaping the landscape through their operational focuses. Novartis (CH) emphasizes innovation in drug development, particularly in the area of gene therapy for retinal diseases, while Johnson & Johnson (US) is enhancing its portfolio through strategic acquisitions and expanding its surgical devices segment. Alcon (CH) is concentrating on digital transformation, integrating advanced technologies into its product offerings, which collectively influences the competitive environment by fostering a culture of continuous improvement and responsiveness to market needs. In terms of business tactics, companies are increasingly localizing manufacturing to reduce costs and enhance supply chain efficiency. The market structure appears moderately fragmented, with several key players holding substantial market shares. This fragmentation allows for a diverse range of products and services, yet the collective influence of major companies like Merck (DE) and Bausch + Lomb (CA) is significant, as they drive innovation and set industry standards. In December 2025, Novartis (CH) announced a collaboration with a leading Indian biotech firm to develop a novel treatment for diabetic retinopathy. This strategic move is likely to enhance Novartis's position in the Indian market by leveraging local expertise and accelerating the development of therapies tailored to regional needs. Such collaborations may also facilitate quicker regulatory approvals and market entry. In November 2025, Johnson & Johnson (US) launched a new line of advanced intraocular lenses designed to improve patient outcomes in cataract surgery. This product introduction not only reflects the company's commitment to innovation but also positions it competitively against other players in the market. The focus on enhancing surgical outcomes aligns with the growing demand for high-quality ophthalmic solutions in India. In October 2025, Alcon (CH) unveiled a digital platform aimed at improving patient engagement and education regarding eye health. This initiative underscores Alcon's strategy to integrate technology into its offerings, potentially leading to better patient adherence and satisfaction. By prioritizing digital solutions, Alcon is likely to differentiate itself in a crowded marketplace, appealing to tech-savvy consumers and healthcare providers alike. As of January 2026, current trends in the ophthalmic drugs and devices market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI). Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in driving innovation and enhancing product offerings. The competitive landscape is shifting from a focus on price-based competition to one centered on technological advancements and supply chain reliability. This evolution suggests that future differentiation will hinge on the ability to innovate and respond to the dynamic needs of the market. ## Recent News & Developments The recent developments in the India Ophthalmic Drugs and Devices Market are marked by significant advancements and activities involving several major players. Allergan and Novartis are expanding their product lines, with recent approvals showcasing innovative treatments in glaucoma and ocular surface disease. In August 2023, Lupin Pharmaceuticals announced a robust pipeline for ophthalmic diseases, emphasizing research efforts aimed at addressing unmet needs in the market. Dr. Reddy's Laboratories continues to strengthen its presence with new partnerships aimed at producing advanced drug delivery systems. Merck launched new therapies targeted for retinal diseases, contributing to growth in market valuation alongside strong competition from Alcon and Johnson and Johnson. In terms of mergers and acquisitions, there has been notable activity, particularly in August 2023, when Aerie Pharmaceuticals acquired a strategic partnership with Bausch Health, further aligning itself in the ophthalmic market. The Indian government's recent initiatives to improve healthcare access, including ophthalmic care, have spurred market growth, with expenditures in healthcare projected to rise significantly by the end of 2024. These developments reflect an evolving landscape where innovation meets rising healthcare demands among the Indian population. ## Report Scope | MARKET SIZE 2024 | 2.18(USD Billion) | | --- | --- | | MARKET SIZE 2025 | 2.33(USD Billion) | | MARKET SIZE 2035 | 3.79(USD Billion) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 5.14% (2024 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Billion | | Key Companies Profiled | Novartis (CH), Allergan (IE), Bausch + Lomb (CA), Johnson & Johnson (US), Santen Pharmaceutical (JP), Alcon (CH), Merck (DE), Pfizer (US), Hoya Corporation (JP) | | Segments Covered | Application, Device Type, End User | | Key Market Opportunities | Emergence of advanced diagnostic tools enhances treatment accessibility in the india ophthalmic drugs devices market. | | Key Market Dynamics | Rising demand for advanced ophthalmic devices drives innovation and competition in India's healthcare sector. | | Countries Covered | India | ## Frequently Asked Questions **Q: What is the current valuation of the India ophthalmic drugs and devices market?** A: The market valuation was 2.18 USD Billion in 2024. **Q: What is the projected market size for the India ophthalmic drugs and devices market by 2035?** A: The market is projected to reach 3.79 USD Billion by 2035. **Q: What is the expected CAGR for the India ophthalmic drugs and devices market during the forecast period?** A: The expected CAGR for the market from 2025 to 2035 is 5.14%. **Q: Which segments are included in the India ophthalmic drugs and devices market?** A: The market segments include applications, device types, and end users. **Q: What was the valuation of the cataract surgery segment in 2024?** A: The cataract surgery segment was valued at 0.87 USD Billion in 2024. **Q: How much is the glaucoma treatment segment expected to grow by 2035?** A: The glaucoma treatment segment is projected to grow from 0.43 USD Billion in 2024 to 0.76 USD Billion by 2035. **Q: Which companies are considered key players in the India ophthalmic drugs and devices market?** A: Key players include Novartis, Allergan, Bausch + Lomb, Johnson & Johnson, and others. **Q: What is the projected valuation for the surgical instruments segment by 2035?** A: The surgical instruments segment is expected to reach 0.8 USD Billion by 2035. **Q: What was the market size for eye clinics in 2024?** A: The market size for eye clinics was 0.55 USD Billion in 2024. **Q: How does the market for ophthalmic solutions compare between 2024 and 2035?** A: The ophthalmic solutions segment is expected to grow from 0.45 USD Billion in 2024 to 0.74 USD Billion by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/india-ophthalmic-drugs-devices-market-53547*